FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.908,15 +132,77 (+0,35%) Nasdaq
15.350,06 -251,44 (-1,61%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
82,94 +0,21 (+0,25%) Bitcoin EUR
60.161,03 +453,33 (+0,76%)
BridgeBio Pharma, Inc. (BBIO)
| Chiusura precedente | 24,95 |
| Aperto | 24,88 |
| Denaro | 24,53 x 100 |
| Lettera | 24,67 x 500 |
| Min-Max giorno | 24,52 - 25,35 |
| Intervallo di 52 settimane | 12,75 - 44,32 |
| Volume | |
| Media Volume | 1.714.083 |
| Capitalizzazione | 4,543B |
| Beta (5 anni mensile) | 1,03 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,95 |
| Prossima data utili | 02 mag 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 49,00 |
GlobeNewswireBridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on October 06, 2023, the compensation committee of BridgeBio’s board of directors granted nineteen new employees restricted stock units for an aggregate of 227,507 shares of the Company’s common stock. With respect to 120,975 shares of restricted stock units, one-fourth
- GlobeNewswire
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria - Rapid and sustained impact of encaleret on mineral homeostasis was observed, specifically in the normalization of blood calcium, urine calcium and parathyroid hormone (PTH) - No serious adverse events were reported with encaleret and no treatment discontinuations or study withdrawals occurred during the trial - The Phase 3 CALIBRATE t
- GlobeNewswire
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate endpoint in LGDM2I/R9 - Long-term data from the ongoing Phase 2 study of BBP-418 in patients with LGMD2I/R9 at Month 21 demonstrate a well-tolerated safety profile, and stabilization in 10 meter walk test (10MWT), 100-m timed test (100mTT), and the North Star Assessment (NSAD) scores - A sustained decr
